{"id":55611,"date":"2026-02-11T01:41:02","date_gmt":"2026-02-11T00:41:02","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/genomic-and-immune-landscape-of-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-progressing-on-anti-pd1-treatment\/"},"modified":"2026-02-11T01:41:02","modified_gmt":"2026-02-11T00:41:02","slug":"genomic-and-immune-landscape-of-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-progressing-on-anti-pd1-treatment","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/genomic-and-immune-landscape-of-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-progressing-on-anti-pd1-treatment\/","title":{"rendered":"Genomic and immune landscape of recurrent and\/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Feb 10. doi: 10.1158\/2326-6066.CIR-25-0979. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Anti-PD1 therapies improve survival in recurrent\/metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN), but only a minority of patients achieve durable responses. The mechanisms driving resistance to anti-PD1 in SCCHN remain poorly understood. Using the IMMUcan multi-omics workflow, we characterized the molecular and immune profiles of R\/M SCCHN progressing on anti-PD1 treatment and compared them to an anti-PD1-na\u00efve cohort. Tumor biopsies from anti-PD1 resistant SCCHN patients exhibited significantly more EGFR and MYCL amplifications, along with increased MYC pathway alterations. Transcriptomic and proteomic analyses revealed that anti-PD1 secondary resistant SCCHN had increased CD8+ T cell infiltration with higher levels of immune exhaustion markers than primary resistant and na\u00efve SCCHN. Additionally, high B2M expression correlated with greater T cell infiltration and improved survival following anti-PD1 therapy. Tumor cell B2M expression was independent of TMB and PD-L1 expression, suggesting that B2M expression could serve as an additional biomarker for anti-PD1 response.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41666253\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260210194056&amp;v=2.18.0.post22+67771e2\">41666253<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0979\">10.1158\/2326-6066.CIR-25-0979<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Feb 10. doi: 10.1158\/2326-6066.CIR-25-0979. Online ahead of print. ABSTRACT Anti-PD1 therapies improve survival in recurrent\/metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN), but only a minority of patients achieve durable responses. The mechanisms driving resistance to anti-PD1 in SCCHN remain poorly understood. Using the IMMUcan multi-omics workflow, we &#8230; <a title=\"Genomic and immune landscape of recurrent and\/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/02\/11\/genomic-and-immune-landscape-of-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-progressing-on-anti-pd1-treatment\/\" aria-label=\"Read more about Genomic and immune landscape of recurrent and\/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-55611","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/55611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=55611"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/55611\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=55611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=55611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=55611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}